Table 2.

AAVs to deliver nanobodies.

AAV a	Nb Activity b	Nb Conformation c	Results d	Ref.
9	Blocks gelsolin cleavage	Heterodimer	Improved muscle contraction in AGel mice	[72]
9	Blocks RyR2 phosphorylation	Monomer	Lower cardiac fibrosis after rat ischemic heart failure	[73]
5	Enhances α-syn degradation	Monomer-PEST	Motor function protection in PD rat model	[74]
8	Antithrombin blockade	Heterodimer	Restores hemostatic balance in hemophilia A/B mice	[75]
8	Neutralizes influenza virus HA	Homodimer	Protection against lethal influenza virus in mice	[76]
9		Multiple domains		[77]
8	Blocking of PD-1	Monomer	Protection against MC38 tumor challenge	[78]
1	P2X7 modulation	Dimer	Protection against EG7 tumor challenge	[79]
--	Blocks PTCH1 activity	Monomer	Hedgehog pathway activation	[80]
2/1	Actin targeting	Monomer-mNep	In vivo visualization of actin filaments	[81]
1	GFP targeting		Delivery of recombinases to GFP-expressing cells	[82]
2/1		Dimer-Flp	Provides Flp activity in GFP + cells	[83]
2/1		Monomer-Cre	Provides Cre activity in GFP + cells	[84]
5		Monomer-Rpl10a	Capture translating mRNAs from GFP + neurons	[85]
2/8/9	Nb fused to AAV capsid		Redirecting the specificity of AAV particles	[86]

^a AAV serotype; ^b The nanobody (Nb) target protein is underlined; RyR2, ryanodine receptor 2; α-syn, α-synuclein; HA, hemagglutinin; PD-1, programmed death protein-1; P2X7, ATP-gated ion channel P2X7; PTCH1, Hedgehog receptor Patched1; ^c PEST, PEST domain; mNep, far-red fluorescent protein mNeptune2; Rpl10a, large ribosomal subunit protein; ^d AGel, gelsolin amyloidosis; PD, Parkinson disease; GFP +, GFP-expressing cells.